If you are taking a GLP-1 medication and want to become pregnant, arrange the medication conversation before you stop contraception or start trying. You need a plan for your exact product, the last dose, pregnancy protection during the waiting period, and treatment of any condition the medicine has been managing.
There is no single stopping interval for every GLP-1 medicine. US semaglutide labels give an advance stopping interval; US tirzepatide labels do not specify a preconception waiting period. And reports of “Ozempic babies” do not establish that these medicines are fertility treatments.
The practical goal is to leave your appointment with dates and a replacement-care plan, rather than a general instruction to “stop before pregnancy.”
Start with the name on your prescription
Bring the brand, active ingredient, injection or tablet form, current dose, reason for treatment, and last dose date. “My weight-loss shot” leaves out details that change the instructions. This table covers common US semaglutide and tirzepatide products; another medicine needs its own label check.
| Product | What its US label says about planning pregnancy | What to settle with your team |
|---|---|---|
| Ozempic — semaglutide injection | Discontinue at least two months before a planned pregnancy. | Last dose, how long to continue contraception, and the diabetes-care plan. |
| Wegovy — semaglutide injection or tablets | For weight reduction or cardiovascular risk reduction, discontinue at least two months before planned pregnancy. The label also applies that interval to MASH treatment when potential risk outweighs potential benefit. | Confirm the indication and formulation; MASH, a form of liver disease, requires an individualized benefit–risk decision. |
| Zepbound or Mounjaro — tirzepatide injection | Neither US label specifies a fixed interval between the last dose and trying to conceive. Both tell patients to inform their provider about pregnancy plans. | Agree on a stopping date, when trying can begin, and continued contraception until then. Do not substitute the semaglutide interval automatically. |
Sources: current US prescribing information for Ozempic, Wegovy, Zepbound, and Mounjaro.
A drug's half-life describes how its level falls over time. It does not, by itself, establish the date on which pregnancy exposure becomes safe. An internet washout estimate is therefore not a substitute for the product-specific preconception plan. For tirzepatide, the lack of a fixed US label interval is a reason to settle the timing explicitly, not a signal to try immediately after the last injection.
Keep contraception in the plan until you are ready to try
Tirzepatide has a specific precaution for oral hormonal contraception. The Mounjaro and Zepbound label instruction is to switch to a non-oral contraceptive method or add a barrier method for four weeks after starting and for four weeks after every dose increase. The first dose counts. If your next increase occurs when one four-week window finishes, another window begins.
The reason is delayed stomach emptying, which can reduce oral hormonal contraceptive effectiveness. Hormonal contraceptives that are not taken by mouth should not be affected by this interaction. Ask the prescriber or pharmacist which suitable method you will use and when it becomes effective; do not simply stop your pill while arranging a replacement.
Semaglutide's labels do not carry that same four-week contraception instruction. That distinction does not make contraceptive-pill problems irrelevant. If you vomit or have significant diarrhea, check your pill's instructions and ask a pharmacist about additional protection. If sex has already occurred during a possible gap in protection, seek prompt pharmacy or clinical advice about emergency contraception rather than waiting for a missed period. CDC contraceptive-use guidance distinguishes instructions by pill type and circumstances.
A past infertility diagnosis or irregular periods should not stand in for a contraceptive plan. For the separate question of changing bleeding patterns, see our guide to tirzepatide and period changes.
Turn the preconception appointment into a written plan
You can open with: “I would like to start trying around this date. Can we work backward from that and plan both the medication change and my health care afterward?” A hoped-for month is useful even if the exact date is flexible.
Before leaving, fill in these six items:
- The medication decision. Which product am I taking, for which condition, and what is the agreed last dose date?
- The trying date. What is the earliest date the team recommends trying to conceive, and which contraception will cover the time until then?
- Any tirzepatide backup windows. Do my start date or recent dose increases mean I still need the extra four weeks of protection?
- Care after stopping. If I have diabetes, what treatment, glucose checks, and follow-up will replace the current plan? If I am treated for another condition, who will manage it during pregnancy?
- Food and other medicines. How will we support adequate eating if appetite or nausea has been difficult, and review prescriptions, supplements, and prenatal vitamin needs?
- The contact plan. Whom do I call if a pregnancy test is positive before the planned date, especially if another dose is due?
The treatment transition matters as much as the calendar. Poorly controlled diabetes can harm both the pregnant patient and fetus, as the Ozempic and Mounjaro labels explain. Stopping a medicine should not leave a gap in diabetes care. A prescriber and pregnancy-care clinician can coordinate that transition rather than asking you to choose between a medication concern and untreated glucose levels.
If stopping treatment raises concerns about appetite, weight, or losing progress, bring those concerns into this appointment too. They belong in the support plan; you do not need to resolve them before asking for preconception care.
If the pregnancy test is already positive
Contact your prescriber and pregnancy-care team promptly. Share the exact product, dose, last dose date, and the test date. If a dose is due before you can reach the usual clinic, seek timely medical advice rather than waiting for the next routine visit.
For Zepbound, discontinue when pregnancy is recognized and contact your healthcare provider. For Wegovy used for weight reduction or cardiovascular risk reduction, discontinue when pregnancy is recognized. Weight loss offers no benefit during pregnancy and may cause fetal harm. These are product instructions, not a reason to wait for an appointment before acting. Zepbound prescribing information, Wegovy prescribing information.
Ozempic and Mounjaro have different pregnancy wording: use during pregnancy only if the potential benefit justifies the potential fetal risk. Their labels instruct patients to inform the provider about pregnancy. Contact the treating team promptly for the medication decision and glucose-management arrangements; do not leave diabetes untreated. Wegovy used for MASH also has a pregnancy benefit–risk provision that requires the treating team's assessment. Ozempic prescribing information, Mounjaro prescribing information, Wegovy prescribing information.
An exposure before you knew you were pregnant does not establish that harm occurred. Equally, limited human data cannot promise safety. Your team can review the timing and discuss pregnancy follow-up and, where available, an exposure registry. A registry collects information; it does not replace your care.
Why “Ozempic babies” does not mean a fertility treatment
A pregnancy occurring during treatment answers one narrow question: pregnancy was possible for that person. It does not show that the drug caused conception, corrects infertility, or is safe to keep taking during pregnancy. Personal reports have no comparison group and cannot separate treatment from changes in weight, metabolic health, contraception, or other circumstances.
There is research worth understanding without turning it into a promise. A 2023 systematic review included 11 randomized trials involving 840 women with PCOS who had overweight or obesity. The trials used exenatide or liraglutide, sometimes with metformin—not semaglutide or tirzepatide. Only four studies reported pregnancy rates. The pooled analysis found improved natural pregnancy rates, but no statistically clear improvement in total pregnancy or IVF pregnancy rates.
Those findings concern specific treatments and a specific population. They do not provide your chance of conceiving on Ozempic or Zepbound, establish a direct fertility effect for those products, or show that taking a GLP-1 during pregnancy is appropriate. Observing pregnancies after treatment and proving that a particular medicine improves fertility are different kinds of evidence.
If fertility is already a concern, tell the pregnancy-care or fertility team about your GLP-1 prescription. The useful next step is a coordinated plan for your health and the timing of trying, with contraception covering the interval you have agreed on.

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



